Neurohormonal regulation of cardiac ion channels in chronic heart failure

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 2, 2009, Pages 98-105

  Kurokawa, Junko ^a   Abriel, Hugues ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Aldosterone; Angiotensin.II; Arrhythmias; Chronic heart failure; Estrogens; Hormone receptors; Ion channels; Vasopressin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ION CHANNEL; MINERALOCORTICOID ANTAGONIST; NEUROHORMONE; VASOPRESSIN;

ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART FAILURE; HORMONAL REGULATION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUDDEN DEATH;

ANIMALS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HOMEOSTASIS; HUMANS; ION CHANNELS; NEUROTRANSMITTER AGENTS;

EID: 74249090952     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181b2b6d4     Document Type: Review

References (107)

1. Lehnart SE, Ackerman MJ, Benson DW Jr, et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation. 2007;116: 2325-2345.
2. Goldenberg I, Zareba W, Moss AJ. Long QT syndrome. Curr Probl Cardiol. 2008;33:629-694.
3. Benito B, Brugada R, Brugada J, et al. Brugada syndrome. Prog Cardiovasc Dis. 2008;51:1-22.
4. Spooner PM, Albert C, Benjamin EJ, et al. Sudden cardiac death, genes, and arrhythmogenesis: consideration of new population and mechanistic approaches from a national heart, lung, and blood institute workshop, part I. Circulation. 2001;103:2361-2364. (Pubitemid 32448800)
5. Roden DM, Spooner PM. Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol. 1999;10: 1664-1683.
6. Young JB. The global epidemiology of heart failure. Med Clin North Am. 2004;88:1135-1143.
7. Stevenson WG, Stevenson LW. Prevention of sudden death in heart failure. J Cardiovasc Electrophysiol. 2001;12:112-114.
8. Domenighetti AA, Boixel C, Cefai D, et al. Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current downregulation. J Mol Cell Cardiol. 2007;42:63-70.
9. Rivard K, Paradis P, Nemer M, et al. Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization. Cardiovasc Res. 2008;78:53-62.
10. Fischer R, Dechend R, Gapelyuk A, et al. Angiotensin II-induced sudden arrhythmic death and electrical remodeling. Am J Physiol Heart Circ Physiol. 2007;293:H1242-H1253.
11. Wang YH, Shi CX, Dong F, et al. Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor. Br J Pharmacol. 2008;154:429-439.
12. Gonzalez-Juanatey JR, Garcia-Acuna JM, Pose A, et al. Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. Am J Cardiol. 1998;81:170-174.
13. Zankov DP, Omatsu-Kanbe M, Isono T, et al. Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes. Circulation. 2006;113:1278-1286.
14. Benitah JP, Vassort G. Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes. Circ Res. 1999;85:1139-1145.
15. Rougier J-S, Muller O, Berger S, et al. Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of L-type calcium currents in cultured neonatal cardiomyocytes. Pflugers Arch. 2008;456: 407-412.
16. Perrier R, Richard S, Sainte-Marie Y, et al. A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice. J Physiol. 2005;569:153-162.
17. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to lifethreatening arrhythmias. Circulation. 2005;111:3025-3033.
18. Boixel C, Gavillet B, Rougier JS, et al. Aldosterone increases voltagegated sodium current in ventricular myocytes. Am J Physiol Heart Circ Physiol. 2006;290:H2257-H2266.
19. Benitah JP, Perrier E, Gomez AM, et al. Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J Physiol. 2001;537(pt 1):151-160.
20. Ikeda U, Hyman R, Smith TW, et al. Aldosterone-mediated regulation of Na+, K(+)-ATPase gene expression in adult and neonatal rat cardiocytes. J Biol Chem. 1991;266:12058-12066.
21. Muto T, Ueda N, Opthof T, et al. Aldosterone modulates If current through gene expression in cultured neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2007;293:2710-2718. doi:10.1152/ajpheart.01399.2006. (Pubitemid 350106494)
22. Korichneva I, Puceat M, Millanvoye-Van BE, et al. Aldosterone modulates both the Na/H antiport and Cl/HCO3 exchanger in cultured neonatal rat cardiac cells. J Mol Cell Cardiol. 1995;27:2521-2528.
23. Lalevee N, Rebsamen MC, Barrere-lemaire S, et al. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;67: 216-224.
24. Lesouhaitier O, Chiappe A, Rossier MF. Aldosterone increases T-type calcium currents in human adrenocarcinoma (H295R) cells by inducing channel expression. Endocrinology. 2001;142:4320-4330.
25. Rossier MF, Lesouhaitier O, Perrier E, et al. Aldosterone regulation of T-type calcium channels. J Steroid Biochem Mol Biol. 2003;85(2-5): 383-388.
26. Mihailidou AS, Buhagiar KA, Rasmussen HH. Na+ influx and Na(+)- K+ pump activation during short-term exposure of cardiac myocytes to aldosterone. Am J Physiol. 1998;274(1 pt 1):C175-C181.
27. Zhang LM, Wang Z, Nattel S. Effects of sustained beta-adrenergic stimulation on ionic currents of cultured adult guinea pig cardiomyocytes. Am J Physiol Heart Circ Physiol. 2002;282:H880-H889.
28. Rossow CF, Dilly KW, Yuan C, et al. NFATc3-dependent loss of I(to) gradient across the left ventricular wall during chronic beta adrenergic stimulation. J Mol Cell Cardiol. 2008;46:249-256.
29. Rossow CF, Dilly KW, Santana LF. Differential calcineurin/NFATc3 activity contributes to the Ito transmural gradient in the mouse heart. Circ Res. 2006;98:1306-1313.
30. Yamamoto T, Sasaki S, Fushimi K, et al. Vasopressin increases AQP-CD water channel in apical membrane of collecting duct cells in Brattleboro rats. Am J Physiol. 1995;268(6 pt 1):C1546-C1551.
31. Nielsen S, Chou CL, Marples D, et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995;92:1013-1017.
32. Hantash BM, Thomas AP, Reeves JP. Regulation of the cardiac L-type calcium channel in L6 cells by arginine-vasopressin. Biochem J. 2006; 400:411-419.
33. Bonev A, Isenberg G. Arginine-vasopressin induces mode-2 gating in L-type Ca2+ channels (smooth muscle cells of the urinary bladder of the guinea-pig). Pflugers Arch. 1992;420:219-222.
34. Marks TN, Dubyak GR, Jones SW. Calcium currents in the A7r5 smooth muscle-derived cell line. Pflugers Arch. 1990;417:433-439.
35. Galizzi JP, Qar J, Fosset M, et al. Regulation of calcium channels in aortic muscle cells by protein kinase C activators (diacylglycerol and phorbol esters) and by peptides (vasopressin and bombesin) that stimulate phosphoinositide breakdown. J Biol Chem. 1987;262:6947-6950.
36. Zhang S, Hirano Y, Hiraoka M. Arginine vasopressin-induced potentiation of unitary L-type Ca2+ channel current in guinea pig ventricular myocytes. Circ Res. 1995;76:592-599.
37. Drici MD, Burklow TR, Haridasse V, et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 1996;94:1471-1474.
38. Song M, Helguera G, Eghbali M, et al. Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. J Biol Chem. 2001;276:31883-31890.
39. Helguera G, Olcese R, Song M, et al. Tissue-specific regulation of Ca(2+) channel protein expression by sex hormones. Biochim Biophys Acta. 2002;1569(1-3):59-66.
40. Bai CX, Kurokawa J, Tamagawa M, et al. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005;112: 1701-1710.
41. Nakamura H, Kurokawa J, Bai CX, et al. Progesterone regulates cardiac repolarization through a nongenomic pathway. An in vitro patch-clamp and computational modeling study. Circulation. 2007;116:2913-2922.
42. Kurokawa J, Tamagawa M, Harada N, et al. Acute effects of estrogen on the guinea pig and human IKr channels and drug-induced prolongation of cardiac repolarizationJ Physiol. 2008;586:2961-2973.
43. Lip GY, Gibbs CR, Beevers DG. ABC of heart failure: aetiology. BMJ. 2000;320:104-107.
44. Jackson G, Gibbs CR, Davies MK, et al. ABC of heart failure. Pathophysiology. BMJ. 2000;320:167-170.
45. Selektor Y, Weber KT. The salt-avid state of congestive heart failure revisited. Am J Med Sci. 2008;335:209-218.
46. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
47. Francis GS. Pathophysiology of chronic heart failure. Am J Med. 2001; 110(Suppl 1):37-46.
48. Abraham WT, Greenberg BH, Yancy CW. Pharmacologic therapies across the continuum of left ventricular dysfunction. Am J Cardiol. 2008; 102(5A):21G-28G.
49. Burstein B, Nattel S. Atrial structural remodeling as an antiarrhythmic target. J Cardiovasc Pharmacol. 2008;52:4-10.
50. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5:1034-1049.
51. Cleland JG, Dargie HJ, East BW, et al. Total body and serum electrolyte composition in heart failure: the effects of captopril. Eur Heart J. 1985;6: 681-688.
52. Cleland JG, Dargie HJ. Arrhythmias, catecholamines and electrolytes. Am J Cardiol. 1988;62:55A-59A.
53. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999;42:270-283.
54. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004;95:754-763.
55. Nass RD, Aiba T, Tomaselli GF, et al. Mechanisms of disease: ion channel remodeling in the failing ventricle. Nat Clin Pract Cardiovasc Med. 2008;5:196-207.
56. Michael G, Xiao L, Qi XY, et al. Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. Cardiovasc Res. 2008;81:491-499. doi:10.1093/cvr/cvn266. In press.
57. Nattel S, Maguy A, Le Bouter S, et al. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 2007;87:425-456. (Pubitemid 47084677)
58. Trautwein W, Kassebaum DG, Nelson RM, et al. Electrophysiological study of human heart muscle. Circ Res. 1962;10:306-312.
59. Marionneau C, Brunet S, Flagg TP, et al. Distinct cellular and molecular mechanisms underlie functional remodeling of repolarizing K+ currents with left ventricular hypertrophy. Circ Res. 2008;102:1406-1415.
60. Guo D, Young L, Patel C, et al. Calcium-activated chloride current contributes to action potential alternations in left ventricular hypertrophy rabbit. Am J Physiol Heart Circ Physiol. 2008;295:H97-H104.
61. Carmeliet E, Vereecke J. Cardiac Cellular Electrophysiology. Boston, MA: Kluwer Academic Publishers; 2002.
62. Sun Y, Weber KT. RAS and connective tissue in the heart. Int J Biochem Cell Biol. 2003;35:919-931.
63. Zhang C, Yasuno S, Kuwahara K, et al. Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy. Circ J. 2006;70:335-341.
64. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299-307.
65. Lombes M, Alfaidy N, Eugene E, et al. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 betahydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92: 175-182.
66. Firsov D, Muller OG. Aldosterone action in the heart. Pflugers Arch. 2003;446:328-333.
67. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
68. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
69. Young M, Funder JW. Aldosterone and the heart. Trends Endocrinol Metab. 2000;11:224-226.
70. Wang Q, Clement S, Gabbiani G, et al. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under normal salt diet. Am J Physiol Renal Physiol. 2004;286:1178-1184. doi:10.1152/ajprenal.00386.2003. (Pubitemid 38656375)
71. Wagner M, Rudakova E, Volk T. Aldosterone-induced changes in the cardiac L-type Ca(2+) current can be prevented by antioxidants in vitro and are absent in rats on low salt diet. Pflugers Arch. 2008;457:339-349.
72. Chiang CS, Huang CH, Chieng H, et al. The CaV3.2 T-type Ca2+ channel is required for pressure overload-induced cardiac hypertrophy in mice. Circ Res. 2009;104:522-530. doi10.1161/CIRCRESAHA.108.184051.
73. Mihailidou AS, Mardini M, Funder JW. Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology. 2004;145:773-780.
74. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids. 2005;70(5-7): 347-351.
75. Mihailidou AS, Bundgaard H, Mardini M, et al. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na(+)-K(+) pump. Circ Res. 2000;86:37-42.
76. Feldman DS, Elton TS, Sun B, et al. Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiovasc Med. 2008;5:208-218.
77. Satoh N, Suter TM, Liao R, et al. Chronic alpha-adrenergic receptor stimulation modulates the contractile phenotype of cardiac myocytes in vitro. Circulation. 2000;102:2249-2254.
78. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res. 1985;56:884-894.
79. Sato Y, Adachi-Akahane S, Prados P, et al. Desensitization and selective down-regulation of rat cardiac beta 1-adrenoceptors by prolonged in vivo infusion of T-0509, a beta 1-adrenoceptor full agonist. Jpn J Pharmacol. 1995 69:343-350.
80. Ungerer M, Bohm M, Elce JS, et al. Altered expression of betaadrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454-463.
81. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
82. Xiao RP, Cheng H, Zhou YY, et al. Recent advances in cardiac beta(2)- adrenergic signal transduction. Circ Res. 1999;85:1092-1100.
83. Keys JR, Koch WJ. The adrenergic pathway and heart failure. Recent Prog Horm Res. 2004;59:13-30.
84. He JQ, Balijepalli RC, Haworth RA, et al. Crosstalk of beta-adrenergic receptor subtypes through Gi blunts beta-adrenergic stimulation of Ltype Ca2+ channels in canine heart failure. Circ Res. 2005;97:566-573.
85. Xiao RP, Zhang SJ, Chakir K, et al. Enhanced Gi signaling selectively negates {beta}2-adrenergic receptor (AR)- but not {beta}1-ARmediated positive inotropic effect in myocytes from failing rat hearts. Circulation. 2003;108:1633-1639.
86. Xiao RP, Avdonin P, Zhou YY, et al. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res. 1999;84:43-52.
87. Steinberg SF. The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ Res. 1999;85:1101-1111.
88. Chen-Izu Y, Xiao RP, Izu LT, et al. G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels. Biophys J. 2000;79:2547-2556.
89. Dilly KW, Kurokawa J, Terrenoire C, et al. Overexpression of beta 2-adrenergic receptors PKA phosphorylates and modulates slow delayed rectifier potassium channels expressed in murine heart: evidence for receptor/channel co-localization. J Biol Chem. 2004;279:40778-40787. doi:10.1074/jbc.M406010200. (Pubitemid 39287674)
90. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of betaadrenergic signaling in heart failure? Circ Res. 2003;93:896-906.
91. Golden KL, Ren J, Dean A, et al. Norepinephrine regulates the in vivo expression of the L-type calcium channel. Mol Cell Biochem. 2002;236 (1-2):107-114.
92. Akuzawa-Tateyama M, Tateyama M, Ochi R. Sustained beta-adrenergic stimulation increased L-type Ca2+ channel expression in cultured quiescent ventricular myocytes. J Physiol Sci. 2006;56:165-172.
93. Clark AL, Cleland JG. The control of adrenergic function in heart failure: therapeutic intervention. Heart Fail Rev. 2000;5:101-114.
94. Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004;1:45-50.
95. Finley JJ IV, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation. 2008;118:410-421.
96. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
97. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005;95(Suppl 1):8-13.
98. Furukawa T, Kurokawa J. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: implication for the gender difference in cardiac arrhythmias. Pharmacol Ther. 2007;115: 106-115.
99. Douglas PS, Katz SE, Weinberg EO, et al. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol. 1998;32:1118-1125.
100. Node K, Kitakaze M, Kosaka H, et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels. Circulation. 1997;96: 1953-1963.
101. McHugh NA, Cook SM, Schairer JL, et al. Ischemia- and reperfusioninduced ventricular arrhythmias in dogs: effects of estrogen. Am J Physiol. 1995;268(6 pt 2):H2569-H2573.
102. Farhat MY, Chen MF, Bhatti T, et al. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharmacol. 1993;110:719-723.
103. Kurokawa J, Suzuki T, Furukawa T. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: acute effects of female hormones on cardiac ion channels and cardiac repolarization. J Pharmacol Sci. 2009;109:334-340.
104. Bai CX, Namekata I, Kurokawa J, et al. Role of nitric oxide in Ca2+ sensitivity of the slowly activating delayed rectifier K+ current in cardiac myocytes. Circ Res. 2005;96:64-72.
105. Furukawa T, Kurokawa J, Clancy CE. A combined approach using patch-clamp study and computer simulation study for understanding long QT syndrome and TdP in women. Curr Cardiol Rev. 2008;4: 157-169.
106. Vandecasteele G, Verde I, Rucker-Martin C, et al. Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J Physiol. 2001;533(pt 2):329-340.
107. Asada K, Kurokawa J, Furukawa T. Redox- and calmodulin-dependent S-nitrosylation of the KCNQ1 channel. J Biol Chem. 2009;284: 6014-6020.